Wang Ningqun, Li Jie, Huang Xiaobo, Chen Wenqiang, Chen Yujing
Department of Traditional Chinese Medicine, Xuanwu Hospital, Capital Medical University, 45 Changchun Street, Beijing 100053, China.
Department of Respiratory Medicine, Dongzhimen Hospital of Beijing University of Chinese Medicine, Beijing 100700, China.
Evid Based Complement Alternat Med. 2016;2016:6134593. doi: 10.1155/2016/6134593. Epub 2016 Dec 5.
Moderate-to-severe asthma has a substantial impact on the health-related quality of life (HR-QOL) of the patients. is a traditional Chinese medicine that is evaluated clinically for the treatment of many diseases, such as chronic allograft nephropathy, diabetic kidney disease, and lung fibrosis. In order to investigate the effects of on patients with moderate-to-severe persistent asthma, 120 subjects were randomized to receive Corbin capsule containing for 3 months (treatment group, = 60), whereas the control group ( = 60) did not receive treatment with Corbin capsule. Inhaled corticosteroid and as-needed -agonists were used in the treatment of both groups. HR-QOL was measured with the Juniper's Asthma Quality of Life Questionnaire (AQLQ). The incidence of asthma exacerbation, pulmonary function testing, and serum measurements of inflammatory mediators were also evaluated. The results showed that the treatment group indicated a significant increase in AQLQ scores and lung function compared with the control group. The expression levels of the inflammation markers IgE, ICAM-1, IL-4, and MMP-9 in the serum were decreased and IgG increased in the treatment group compared with the control group. Therefore, the conclusion was reached that a formulation of improved the HR-QOL, asthma symptoms, lung function, and inflammatory profile of the patients with moderate-to-severe asthma. This trial is registered with ChiCTR-IPC-16008730.
中重度哮喘对患者的健康相关生活质量(HR-QOL)有重大影响。[某种中药名称]是一种经临床评估可用于治疗多种疾病的中药,如慢性移植肾肾病、糖尿病肾病和肺纤维化。为了研究[某种中药名称]对中重度持续性哮喘患者的影响,将120名受试者随机分为两组,一组接受含[某种中药名称]的Corbin胶囊治疗3个月(治疗组,n = 60),而对照组(n = 60)未接受Corbin胶囊治疗。两组治疗均使用吸入性糖皮质激素和按需使用的β-激动剂。采用朱尼珀哮喘生活质量问卷(AQLQ)测量HR-QOL。还评估了哮喘急性加重的发生率、肺功能测试以及炎症介质的血清检测结果。结果显示,与对照组相比,治疗组的AQLQ评分和肺功能显著提高。与对照组相比,治疗组血清中炎症标志物IgE、ICAM-1、IL-4和MMP-9的表达水平降低,IgG升高。因此,得出结论:[某种中药名称]制剂改善了中重度哮喘患者的HR-QOL、哮喘症状、肺功能和炎症指标。本试验已在中国临床试验注册中心注册,注册号为ChiCTR-IPC-16008730。